FDA approval moves trastuzumab deruxtecan in combination with pertuzumab into frontline treatment of unresectable or ...
22h
AstraZeneca, Daiichi Sankyo's Enhertu Regimen Greenlit as First-line Breast Cancer Treatment in US
AstraZeneca (AZN.L, AZN.ST) on Monday said Enhertu plus pertuzumab won approval in the US as the first-line treatment of ...
FDA approves AstraZeneca and Daiichi's Enhertu combo for first-line HER2-positive breast cancer, while the EU clears Saphnelo ...
Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients ...
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the USA ...
Enhertu is already approved as a second-line or later treatment for HER2-positive breast cancer, along with other indications ...
AstraZeneca PLC AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster antibody-drug conjugate (ADC), Enhertu, for first-line use in breast cancer.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved additional indications for its PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary ...
The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu) plus pertuzumab as first-line therapy for unresectable or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback